Eribulin in mTNBC Patients

An Observational, Retrospective Study of Eribulin in Advanced Breast Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04541420

Enrollment

208

Registered

2020-09-09

Start date

2019-12-15

Completion date

2020-12-20

Last updated

2021-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

Eribulin, TNBC

Brief summary

To evaluate the efficacy and safety of Eribulin in patients with advanced breast cancer.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Healthy volunteers

Inclusion criteria

1. Advanced breast cancer included unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer. 2. Eribulin treatment of advanced breast cancer for at least one cycle, between Dec 2019 and Aug 2020. 3. Available medical history.

Exclusion criteria

1\. Incomplete medical history.

Design outcomes

Primary

Measure	Time frame	Description
PFS	6 weeks	Progression free survival
Adverse events	6 weeks	Number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)

Countries

China

Outcome results